Annexon (ANNX) Competitors $3.15 +0.08 (+2.61%) Closing price 04:00 PM EasternExtended Trading$3.18 +0.04 (+1.11%) As of 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ANNX vs. GPCR, SDGR, ABCL, JANX, RCUS, SNDX, ARDX, STOK, XERS, and ZYMEShould you be buying Annexon stock or one of its competitors? The main competitors of Annexon include Structure Therapeutics (GPCR), Schrodinger (SDGR), AbCellera Biologics (ABCL), Janux Therapeutics (JANX), Arcus Biosciences (RCUS), Syndax Pharmaceuticals (SNDX), Ardelyx (ARDX), Stoke Therapeutics (STOK), Xeris Biopharma (XERS), and Zymeworks (ZYME). These companies are all part of the "pharmaceutical products" industry. Annexon vs. Its Competitors Structure Therapeutics Schrodinger AbCellera Biologics Janux Therapeutics Arcus Biosciences Syndax Pharmaceuticals Ardelyx Stoke Therapeutics Xeris Biopharma Zymeworks Annexon (NASDAQ:ANNX) and Structure Therapeutics (NASDAQ:GPCR) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, analyst recommendations, risk, media sentiment, institutional ownership, dividends, valuation and earnings. Do analysts rate ANNX or GPCR? Annexon currently has a consensus price target of $12.50, indicating a potential upside of 296.83%. Structure Therapeutics has a consensus price target of $68.67, indicating a potential upside of 141.36%. Given Annexon's higher probable upside, research analysts clearly believe Annexon is more favorable than Structure Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Annexon 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40Structure Therapeutics 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89 Is ANNX or GPCR more profitable? Structure Therapeutics' return on equity of -21.31% beat Annexon's return on equity.Company Net Margins Return on Equity Return on Assets AnnexonN/A -70.04% -57.67% Structure Therapeutics N/A -21.31%-20.34% Does the media refer more to ANNX or GPCR? In the previous week, Annexon had 6 more articles in the media than Structure Therapeutics. MarketBeat recorded 7 mentions for Annexon and 1 mentions for Structure Therapeutics. Annexon's average media sentiment score of 1.21 beat Structure Therapeutics' score of 0.53 indicating that Annexon is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Annexon 4 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Structure Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do institutionals & insiders believe in ANNX or GPCR? 91.8% of Structure Therapeutics shares are held by institutional investors. 11.9% of Annexon shares are held by company insiders. Comparatively, 5.6% of Structure Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has stronger earnings and valuation, ANNX or GPCR? Structure Therapeutics is trading at a lower price-to-earnings ratio than Annexon, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnnexonN/AN/A-$138.20M-$1.29-2.44Structure TherapeuticsN/AN/A-$122.53M-$1.05-27.10 Which has more volatility and risk, ANNX or GPCR? Annexon has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500. Comparatively, Structure Therapeutics has a beta of -1.65, meaning that its share price is 265% less volatile than the S&P 500. SummaryStructure Therapeutics beats Annexon on 8 of the 14 factors compared between the two stocks. Get Annexon News Delivered to You Automatically Sign up to receive the latest news and ratings for ANNX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ANNX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ANNX vs. The Competition Export to ExcelMetricAnnexonMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$337.35M$3.36B$6.11B$10.56BDividend YieldN/A2.29%5.69%4.75%P/E Ratio-2.4421.5785.4827.60Price / SalesN/A475.54621.72242.93Price / CashN/A47.1237.9261.55Price / Book1.1510.1413.136.76Net Income-$138.20M-$52.31M$3.30B$275.88M7 Day Performance3.96%6.72%5.29%3.72%1 Month Performance42.53%15.01%9.94%10.22%1 Year Performance-54.28%29.34%87.78%35.86% Annexon Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ANNXAnnexon2.9696 of 5 stars$3.15+2.6%$12.50+296.8%-50.0%$337.35MN/A-2.4460Positive NewsAnalyst ForecastGPCRStructure Therapeutics3.0857 of 5 stars$25.30+1.2%$68.67+171.4%-29.6%$1.44BN/A-24.10136Analyst ForecastSDGRSchrodinger3.2241 of 5 stars$20.04+3.8%$27.83+38.9%+18.7%$1.42B$207.54M-8.08790Analyst ForecastABCLAbCellera Biologics2.6666 of 5 stars$4.87+2.7%$8.00+64.3%+119.4%$1.42B$28.83M-8.85500Analyst ForecastJANXJanux Therapeutics1.8195 of 5 stars$23.70+2.0%$78.31+230.4%-48.6%$1.40B$439K-13.1730Analyst ForecastRCUSArcus Biosciences1.9118 of 5 stars$13.34+3.9%$21.14+58.5%-19.0%$1.37B$258M-4.21500News CoverageAnalyst ForecastGap UpSNDXSyndax Pharmaceuticals3.6649 of 5 stars$15.56-0.8%$39.22+152.1%-9.9%$1.35B$23.68M-4.00110Analyst ForecastAnalyst RevisionARDXArdelyx4.3202 of 5 stars$5.63+1.6%$11.70+107.8%-15.7%$1.34B$333.61M-24.4890News CoverageAnalyst ForecastSTOKStoke Therapeutics3.2754 of 5 stars$24.73+2.4%$25.57+3.4%+139.6%$1.32B$36.56M29.09100News CoverageAnalyst ForecastInsider TradeXERSXeris Biopharma2.8724 of 5 stars$8.08-1.2%$7.08-12.3%+182.6%$1.32B$203.07M-38.47290Positive NewsAnalyst ForecastZYMEZymeworks2.1246 of 5 stars$17.23+3.8%$21.43+24.4%+32.1%$1.30B$122.87M-11.49460News CoveragePositive NewsAnalyst Revision Related Companies and Tools Related Companies GPCR Competitors SDGR Competitors ABCL Competitors JANX Competitors RCUS Competitors SNDX Competitors ARDX Competitors STOK Competitors XERS Competitors ZYME Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ANNX) was last updated on 10/8/2025 by MarketBeat.com Staff From Our PartnersU.S. Government Sparking Crypto RallySecond Chances Don't Come Often in Crypto My "Crypto Bull Run Millionaire Blueprint" reveals everything - w...Crypto 101 Media | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredGOLD ALERTGold has shattered records, soaring past $3,800 an ounce... But Stansberry Senior Partner Dr. David "Doc" E...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Annexon, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Annexon With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
